Dr Daniel Elger
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
Dr Liam Evans
Hypha collaborates with pharma/biotech and agrochemical groups in the following areas
1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
+ mg amounts for MetID, quantification standards
+ gram quantities for tox/pharmacological studies
+ includes glucuronides and chemically intractable hydroxyl derivatives
Our microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds
2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library.
+ Used by biotech and pharma to find hit compounds against "difficult-to-hit" targets
+ Molecular weight range mostly between 200 and 400 DA
+ 50% novelty
+ Exclusive rights to develop and commercialise
3. Fermentation and purification of small molecules for semi-synthetic lead optimisation
Hypha Discovery LtdCEO
Advocates Ltd., Pharmaceutical & Healthcare is a global Programme Management and Technical Support Organisation based in Scotland, USA and Hong Kong. Clients include universities, virtual & start-up companies, biotechs, pharmaceutical companies, healthcare organisations and investors involved in developing cures for clinical disorders on a regional basis and with a global focus.
Since 2002, it has been our mission to “accelerate the development pathway towards healthier, extended lives through our competence and capacity to address drug development challenges”.
As a testament to this, our team of scientists, project managers & technical professionals have provided `hands on’ technical support to 17 drug development programmes from discovery to our clients required endpoint, all of which have met their development objectives, whilst maintaining focus on delivery of commercial objectives & investment opportunities.
Discovery to Market Key Services include:
· Grant Funding Support
· Technical Due Diligence / Investor Support
· Project Management
· Discovery & Pre-Clinical Support
· Pharmaceutical Development CMC
· Quality Management
· Regulatory Preparation, Submission & Liaison
· Operational / Commercial CMC
· Supplies / Logistics Management
· Clinical Support
· Medical Devices Expertise
Benefits to our Clients:
· Proven expertise of successfully managing development programmes
· Experienced in all compound classes, the majority of therapeutic areas and routes of administration
· Experts in CMC (Chemistry, Manufacturing & Controls)
· Credible relationships with national regulatory agencies
· Trustworthy relationships with funding bodies
· Bases in UK, USA & HK / trade in local currencies
· We care “caring is a powerful business advantage”
If you would like to discuss any aspect of your drug development needs please email:
Angelina Fisher at: email@example.com, alternatively, please call +44 (0) 7929 671290.
Advocates Pharmaceutical & HealthcareDirector of Corporate Affairs
Dr Rob Grundy
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
· IVR / Web
· Statistical Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #64
Almac GroupDirector Research Alliances, Almac Discovery Ltd
Mr Robert Habib
MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).
Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.
Sphere Fluidics Limited is an innovative Life Sciences company which delivers miniaturised products, systems and collaboration services in field of single cell analysis.
Sphere’s core technology is in the field of high throughput Picodroplet generation and analysis and has significant patent portfolio that protects its core expertise. It enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes.
Uniquely, as well as allowing single cell studies, the systems enable the study of different, large biomolecules that interact with or are secreted by those single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology
Sphere Fluidics' technology enables diverse applications such as study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains.
Sphere Fluidics has established multiple commercial partnerships, received Venture Capital investment and with its founders the Company have received almost £10 million in science and business funding to date.
Sphere Fluidics LtdPrincipal Engineer
Dr Catherine Hunter
CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Crystec SCF technologies can be applied to both small drug molecules and biomolecules.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.
We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large moilecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.
Ms Eva Hurst
About Competitive Drug Development International Ltd.
CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.
Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.
Our working method is hands-on, not just consulting, which means, we don’t just advise you, but actively implement the strategies and plans that we formulate with you. For more information please visit www.cddi.co.
Dr Audrey Jamieson
QCTR is the ONLY CRO to focus exclusively on clinical trials in CNS.
With its subjective assessments and often subjective diagnosis, along with lack of biomarkers and high placebo response, CNS offers unique challenges.
QCTR have over 15 years of experience in CNS covering diseases as diverse as Alzheimer's, TBI, stroke and schizophrenia, and orphan diseases such as Huntington's and FTD.
With a worldwide network of experienced clinicans working in neurology and psychiatry, and experienced staff knowledgable in the therapeutic field, we can plan and execute cost effective clinical trials to meet your company's specific requirements.
QCTR LtdBusiness Development Manager
Dr Allison Jeynes-Ellis
Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventues. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.
We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).